The company plans to launch its product in the fourth quarter of calendar 2008. With this approval, Barr’s US generic injectable portfolio now totals eight products.
The company plans to launch its product in the fourth quarter of calendar 2008. With this approval, Barr’s US generic injectable portfolio now totals eight products.